สีปกติ
ขาวดำ
ดำ-เหลือง
FDA has placed emphasis on the management of the Attention Deficit Hyperactivity Disorder (ADHD) Medications by sharing knowledge with more than 1,550 hospitals through both onsite and online methods. This initiative aims to strengthen service standards and improve operations for the utmost advantage of the people.
Dr. Narong Aphikulvanich, Secretary-General of Food and Drug Administration stated that FDA is the organization responsible for granting permission narcotics substances used for the medical purpose and supporting the procurement and acquisition of public and private hospitals. FDA has implemented the Action Plan for 2024 which includes the Capacity Building that aims to provide knowledge and correct understanding to the concerned hospitals in utilizing the narcotics substances which must be in line with the related regulations and laws. ADHD medications are regulated by the FDA and in order to ensure that patients will obtain the continuous medications so FDA organized a training session on the topic of “Role and Responsibility of FDA on the Management of the Attention Deficit Hyperactivity Disorder Medications” on Wednesday, 19 June 2024 at the Conference Room, floor 9th of OSSC, FDA. This training was conducted both onsite and online (Zoom meeting) with the invited professional speakers to deliver knowledge on the topic and other related issues. The onsite training was attended by 50 participants while more than 1,500 public and private hospitals and interested organizations across the country joined the training online.
The Secretary-General of FDA concluded that the training on FDA’s role and responsibility on the management of the Attention Deficit Hyperactivity Disorder Medications will enhance knowledge and provide a correct understanding of the use of the narcotics substances for medical purpose to the hospitals and to the Narcotics Revolving Fund Group. This training will raise the standard of service and strengthen good relations among the stakeholders. Moreover, it will help develop and continually improve the FDA’s operation for maximizing benefits to the people.
*******************************************
News Publication Date: 20 June 2024
